Semaglutide (often abbreviated SEMA in research circles) is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that has transformed the treatment of type 2 diabetes and chronic obesity. Originally developed as a once-weekly injectable and later reformulated as an oral tablet, semaglutide works by mimicking the body’s own incretin hormone to regulate appetite, blood sugar, and body weight. This guide explains what semaglutide is, how it works, what the clinical evidence shows, and practical considerations for understanding its use.

Note on naming: Semaglutide is marketed under the brand names Ozempic (for type 2 diabetes), Wegovy (for chronic weight management), and Rybelsus (oral form). In research peptide contexts it is frequently called SEMA.

Fast Answer / Executive Summary

Semaglutide is a GLP-1 receptor agonist that mimics the gut-derived hormone GLP-1 to suppress appetite, slow gastric emptying, stimulate glucose-dependent insulin secretion, and reduce glucagon output. In large randomized trials, once-weekly subcutaneous semaglutide at 2.4 mg produced an average 14.9% reduction in body weight over 68 weeks in adults with obesity.[1] It carries FDA approval for type 2 diabetes (Ozempic, 2017) and chronic weight management (Wegovy, 2021).

Core Concepts & Key Entities

What is GLP-1?
GLP-1 is an incretin hormone secreted by L-cells in the small intestine after meals. It stimulates insulin release, suppresses glucagon, slows gastric emptying, and signals satiety to the brain’s hypothalamus. Semaglutide is structurally similar to native GLP-1 but modified at positions 8 and 34 to resist DPP-4 degradation, giving it a half-life of approximately 7 days.[2]

Key mechanisms, in one line each:

  • Appetite suppression: Activates GLP-1 receptors in the hypothalamus and brainstem, reducing hunger signals and caloric intake.[1]
  • Glucose-dependent insulin secretion: Stimulates pancreatic β-cells to release insulin only when glucose is elevated, reducing hypoglycemia risk.[2]
  • Glucagon suppression: Reduces hepatic glucose output by suppressing α-cell glucagon release.[2]
  • Delayed gastric emptying: Slows the rate at which food leaves the stomach, blunting post-meal glucose spikes and extending satiety.[2]
  • Cardiovascular protection: The SUSTAIN-6 and SELECT trials demonstrate significant reductions in major adverse cardiovascular events (MACE) independent of weight loss.[3]

Where the evidence is strongest vs. emerging:

  • Strongest (multiple large RCTs): Weight loss in obesity, glycemic control in type 2 diabetes, cardiovascular risk reduction in high-risk patients.
  • Emerging (smaller or early trials): Non-alcoholic steatohepatitis (NASH), kidney protection, addiction and craving modulation.

Step-by-Step: How to Work With Semaglutide

Educational note: Semaglutide is FDA-approved and available by prescription. The following discusses its general use for educational purposes only—not as medical advice.

Step 1 — Understand the titration principle

Always start at the lowest dose and escalate slowly. The approved titration for weight management (Wegovy) is:

  • Weeks 1–4: 0.25 mg once weekly
  • Weeks 5–8: 0.5 mg once weekly
  • Weeks 9–12: 1.0 mg once weekly
  • Weeks 13–16: 1.7 mg once weekly
  • Week 17+: 2.4 mg once weekly (maintenance)

Slow titration minimizes gastrointestinal side effects (nausea, vomiting, diarrhea) that are most prominent during the initiation phase.[1]

Step 2 — Route and site of administration

Semaglutide is administered as a subcutaneous injection into the abdomen, thigh, or upper arm. Rotate injection sites each week. The injection can be given at any time of day, with or without food.

Step 3 — Research peptide reconstitution math

For research purposes, lyophilized semaglutide peptide (e.g., 5 mg vial) is reconstituted with bacteriostatic water. See the SEMA 5 mg Dosage Protocol on this site for step-by-step reconstitution math and dosing tables.

Step 4 — Monitor for side effects

  • Common: Nausea, vomiting, diarrhea, constipation (typically improve over weeks).
  • Less common: Injection site reactions, headache, fatigue, hypoglycemia (when combined with insulin or sulfonylureas).
  • Rare but serious: Pancreatitis, gallbladder disease, medullary thyroid carcinoma risk (contraindicated in those with personal/family history of MTC or MEN2).[4]

Step 5 — Lifestyle integration

Semaglutide is most effective as part of a reduced-calorie diet and increased physical activity program. Clinical trials paired it with lifestyle counseling, which may explain the substantial weight-loss outcomes observed.[1]

Comparison & Alternatives

Answer-first: Semaglutide is the leading GLP-1 agonist for weight loss by magnitude of effect; tirzepatide (GLP-1/GIP dual agonist) achieves greater weight loss but with a different side-effect profile and mechanism.

Agent Mechanism Avg. Weight Loss Dosing FDA Approval
Semaglutide (SEMA) GLP-1 agonist ~15% (STEP 1) Once weekly SC Yes (Wegovy 2021)
Tirzepatide GLP-1 / GIP dual agonist ~21% (SURMOUNT-1) Once weekly SC Yes (Zepbound 2023)
Retatrutide (RETA) GLP-1 / GIP / glucagon triple agonist ~24% (Phase 2) Once weekly SC Investigational
Liraglutide GLP-1 agonist ~8% (SCALE) Once daily SC Yes (Saxenda 2014)

FAQs

1) What is semaglutide?
Semaglutide is a GLP-1 receptor agonist peptide drug that mimics the incretin hormone GLP-1. It was developed by Novo Nordisk, received FDA approval for type 2 diabetes in 2017 (Ozempic), and for chronic weight management in 2021 (Wegovy). It is administered as a once-weekly subcutaneous injection.[2]

2) How much weight can semaglutide cause you to lose?
In the landmark STEP 1 trial, adults with obesity receiving semaglutide 2.4 mg weekly for 68 weeks lost an average of 14.9% of body weight versus 2.4% in the placebo group. Nearly 86% of participants lost ≥5% of their body weight.[1]

3) Why does semaglutide suppress appetite so effectively?
Semaglutide crosses the blood-brain barrier and activates GLP-1 receptors in the hypothalamus and brainstem, regions that control hunger and satiety. This central action reduces caloric intake, while peripheral effects (delayed gastric emptying) extend feelings of fullness after meals.[2]

4) Is semaglutide safe long-term?
Long-term data from the SUSTAIN and SELECT trials show a favorable safety profile over 2+ years. The most common side effects—nausea and GI upset—typically diminish over time. Semaglutide carries a black-box warning for medullary thyroid carcinoma based on rodent studies; it is contraindicated in patients with a personal or family history of MTC or MEN2.[4]

5) How does semaglutide differ from ozempic and wegovy?
Ozempic and Wegovy contain the same active ingredient—semaglutide—but at different approved doses and indications. Ozempic (up to 2.0 mg weekly) is approved for type 2 diabetes and cardiovascular risk reduction. Wegovy (up to 2.4 mg weekly) is approved specifically for chronic weight management.

6) What happens when you stop taking semaglutide?
Clinical data show that most participants regain the majority of lost weight within one to two years of discontinuing semaglutide, along with reversal of cardiometabolic improvements. This underscores that it is a chronic treatment, not a short-term intervention, and that lifestyle changes are critical to sustaining benefits.[1]

Evidence Highlights

  • STEP 1 (NEJM, 2021): 1,961 adults with obesity; semaglutide 2.4 mg weekly vs placebo; 14.9% mean weight loss at 68 weeks. Takeaway: Strongest weight-loss RCT for a GLP-1 agonist at time of publication.[1]
  • SELECT trial (NEJM, 2023): 17,604 adults with overweight/obesity plus cardiovascular disease; semaglutide 2.4 mg weekly reduced MACE by 20% vs placebo over ~33 months. Takeaway: First obesity drug to show major cardiovascular benefit.[3]
  • SUSTAIN-6 (NEJM, 2016): In type 2 diabetes patients, semaglutide reduced MACE by 26% vs placebo. Takeaway: Cardiovascular protection established early in diabetes setting.
  • Pharmacology (Lau et al., 2015): Molecular basis for semaglutide’s extended half-life—albumin binding and DPP-4 resistance via amino acid substitutions at positions 8 and 34.[2]

Next Steps

If you are researching semaglutide dosing and reconstitution:

If you are comparing GLP-1 options:

  • See our article on What Is Retatrutide for the triple agonist alternative, or What Is a GLP-1? for a comprehensive overview of the drug class.

Takeaway: Semaglutide is the best-evidenced GLP-1 agonist for weight management to date, with robust Phase 3 data and cardiovascular benefits; its primary limitations are cost, GI side effects during titration, and weight regain upon discontinuation.